Charleston, South Carolina with the assistance and financial support of the South Carolina Research Authority (SCRA). Its team is comprised of medical experts and business professionals from around the world with extensive experience in innovation, development, and clinical research.

Alzheimer’s disease (AD) is a neurodegenerative disease characterized by cognitive decline, functional impairment, and dementia. An estimated 6.7 million Americans of all ages had Alzheimer’s disease in 2023 (Centers for Disease Control) and more than 55 million people are believed to be living with Alzheimer’s disease or other dementias worldwide (Alzheimer’s Disease International). The number of people with dementia is projected to double by 2040 and more than triple by 2060. The global economic burden of AD and related dementias is projected to reach $16.9 trillion by 2050.

The disease is caused by the accumulation of amyloid plaque (Aβ42) in the brain, which can begin up to 20 years before the appearance of symptoms. Recently approved FDA drugs for treating AD have demonstrated their ability to decrease the brain amyloid load. Data indicate that treatments for AD are significantly more effective when given to asymptomatic individuals, but there has been no effective way to identify these patients until now. NeuroScreen™ assay services will change the world by detecting the disease in millions of asymptomatic individuals